King Wealth Management Group’s Aldeyra Therapeutics ALDX Stock Holding History

King Wealth Management Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27K	Buy	12,700 +800	+7%	+$1.38K	﹤0.01%	175
2026 Q1	$20K	Buy	11,900 +1,100	+10%	+$4.82K	﹤0.01%	158
2025 Q4	$56K	Sell	10,800 -300	-3%	-$1.54K	0.01%	163
2025 Q3	$58K	Sell	11,100 -1,000	-8%	-$5.21K	0.01%	159
2025 Q2	$46K	Buy	+12,100	New	+$31.3K	0.01%	158
2025 Q1	–	Sell	-13,500	Closed	-$67K	–	158
2024 Q4	$67K	Sell	13,500 -200	-1%	-$1.03K	0.01%	153
2024 Q3	$74K	Buy	13,700 +2,700	+25%	+$12.9K	0.01%	150
2024 Q2	$36K	Buy	11,000 +1,000	+10%	+$3.92K	0.01%	143
2024 Q1	$33K	Buy	+10,000	New	+$32.9K	0.01%	145

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

King Wealth Management Group's ALDX Position: Q2 2026 in Review

King Wealth Management Group increased its Aldeyra Therapeutics (ALDX) stake by 6.7% in Q2 2026, buying an estimated $1.38K and bringing the position to 12,700 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #175.

King Wealth Management Group first reported a position in ALDX in Q1 2024 and has held it in 9 quarters since. The position peaked at $74K in Q3 2024. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

King Wealth Management Group held 12,700 shares of Aldeyra Therapeutics worth $27K as of Q2 2026.
King Wealth Management Group bought 800 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.38K.
Aldeyra Therapeutics made up ﹤0.01% of King Wealth Management Group's portfolio in Q2 2026, its #175 holding.
King Wealth Management Group first reported a position in Aldeyra Therapeutics in Q1 2024 and has held it in 9 quarters since.
King Wealth Management Group's Aldeyra Therapeutics position peaked at $74K in Q3 2024.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on King Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.